Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye care company is considering selling itself to disentangle from its debt-laden parent company. The Financial Times ...

Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward ...

Bausch+Lomb, valued at over $10 billion, is exploring a sale to resolve financial issues tied to its parent, Bausch Health, with $21 billion The eye care giant is projected to generate $4.7 ...

One of the most exciting features to look forward to? The Zeiss Multifocal Portrait, which brings professional-grade focal lengths straight to your phone. Imagine being able to shoot stunning ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Bausch + Lomb, one of the world’s largest contact lens suppliers, is exploring a sale as a way to clean ...

The stock of eyecare company Bausch + Lomb Corp. was up 14%on Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its ...

The arena of premium IOLs is changing rapidly. The current choices in PC-IOLs include refractive multifocal IOLs, diffractive multifocal IOLs, and accommodating IOLs. A proper clinician ...